Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Segment Net Loss, Including Disaggregated Components of Operating Expenses

The Company's consolidated and segment net loss, including disaggregated components of operating expenses is as follows (in thousands):

	Year Ended December 31,
	2024			2023
Collaboration revenue - related party	$	2,370		$	2,380
Operating expenses:
Research and development:
Verekitug program:
Asthma indication		28,069			14,537
CRSwNP indication		10,524			3,330
COPD indication		3,115			—
Personnel expenses (including stock-based compensation of $1,162     and $1,073, respectively)		9,911			7,588
Manufacturing costs		6,580			3,373
Professional fees and other		4,767			2,971
Total research and development expenses		62,966			31,799
General and administrative:
Personnel expenses (including stock-based compensation of $4,842    and $2,354, respectively)		10,842			6,352
Professional fees		4,349			3,347
Other (including depreciation of $89 and $60, respectively)		1,977			996
Total general and administrative expenses		17,168			10,695
Total operating expenses		80,134			42,494
Loss from operations		(77,764	)		(40,114	)
Other income (expense):
Change in fair value of preferred stock tranche right liabilities		2,859			15,527
Interest income		12,123			4,165
Other expense, net		(24	)		(115	)
Total other income, net		14,958			19,577
Segment and consolidated net loss	$	(62,806	)	$	(20,537	)